Castle Biosciences to Present at the Piper Jaffray 28th Annual Healthcare Conference


Friendswood, TX – November 22, 2016 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that Derek Maetzold, President and CEO, will be presenting at the Piper Jaffray 28th Annual Healthcare Conference on Tuesday, November 29th, 2016 at 4:50 p.m. EST in New York.

About Castle Biosciences
Castle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and follow up care based on the individual molecular signature of their tumor. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma; www.SkinMelanoma.com) and uveal melanoma (DecisionDx®-UM and DecisionDx®-PRAME; www.MyUvealMelanoma.com), with development programs in other underserved cancers. Castle Biosciences is based in Friendswood, TX (Houston), and has laboratory operations in Phoenix, AZ. More information can be found at www.CastleBiosciences.com.

DecisionDx-Melanoma, DecisionDx-UM and DecisionDx-PRAME are the trademarks of Castle Biosciences, Inc. Any other trademarks are the property of their respective owners.

Investors
James L Dunn, Jr., CFO
866-788-9007
IR@castlebiosciences.com

Media
BMC Communications, LLC
Amy Bonanno
646-513-3117
Abonanno@bmccommunications.com